Rapport Therapeutics Stock Forecast
NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
RAPP analyst consensus
Consensus (14 analysts)
strong_buy
Avg. price target
$63.04+105.68%
- Strong buy 1
- Buy 13
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 14 Wall Street analysts covering Rapport Therapeutics (2026-10-08), 14 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $63.04, with a high estimate of $80.00 and a low estimate of $50.00. The average target implies upside of 105.7% from the current price of $30.65.
The spread between the highest and lowest targets is 60.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RAPP.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 7% |
| Buy | 13 | 93% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $50.00 | +63.13% |
| Average target | $63.04 | +105.68% |
| High target | $80.00 | +161.01% |